371 results for "Neuroplasticity"
Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study
Philosophical Transactions of the Royal Society B Biological Sciences – October 21, 2024
Summary
Individuals receiving psilocybin-assisted neurofeedback reported significant self-reported improvements in daily executive functions, crucial for mental health and physical medicine and rehabilitation. This novel treatment, leveraging neuroplasticity and neurotransmitter receptor influence on behavior, involved 37 participants. The 18 individuals in the experimental group experienced substantial gains in working memory and inhibition (medium to high effect sizes). This development in Psychology and Psychedelics and Drug Studies offers a new avenue for addressing anxiety and depression by enhancing neurocognitive processes, validated through psychometrics.
Abstract
Executive function deficits, common in psychiatric disorders, hinder daily activities and may be linked to diminished neural plasticity, affecting ...
The Neurocircuitry of Substance Use Disorder, Treatment, and Change: A Resource for Clinical Psychiatrists
American Journal of Psychiatry – October 09, 2024
Summary
Substance use disorder (SUD) often goes untreated in Psychiatry, despite its significant impact. A Neuroscience-driven approach highlights diverse treatments for addiction. Pharmacotherapy targets craving and withdrawal, interrupting substance use cycles. Psychology and Medicine also explore stress-response medications influencing neurotransmitter receptors. Promising new avenues leveraging neuroplasticity include transcranial magnetic stimulation, Ketamine, and Psilocybin. These Psychedelics and Drug Studies offer innovative strategies for substance abuse, informing comprehensive care.
Abstract
Substance use disorder (SUD) is common in psychiatric patients and has a negative impact on health and well-being. However, SUD often goes untreate...
Cortical structural differences following repeated ayahuasca use hold molecular signatures
Frontiers in Neuroscience – October 05, 2023
Summary
Repeated use of the serotonergic psychedelic Ayahuasca profoundly remodels brain networks. Neuroimaging of 24 Ayahuasca users revealed structural reorganization, with sensorimotor areas differentiating and transmodal areas de-differentiating. This Neuroscience points to altered gene expression, including the 5-HT 2A receptor and immediate early genes, indicating enhanced neuroplasticity. Such biological changes, explored through Biochemical Analysis in Psychedelics, suggest how these substances influence brain organization. This macroscale effect, linked to Neurotransmitter Receptor Influence, offers insight into the Psychology and behavioral differences observed in experienced users.
Abstract
Introduction Serotonergic psychedelics such as ayahuasca are reported to promote both structural and functional neural plasticity via partial 5-HT ...
Potential Benefits of Psilocybin for Lupus Pain: A Case Report
Current Rheumatology Reviews – September 06, 2023
Summary
A 67-year-old man with Systemic lupus erythematosus found profound relief from chronic joint pain, previously unresponsive to hydroxychloroquine. After a single 6-gram macro-dose of the alkaloid psilocybin, his debilitating pain dramatically improved and remained absent for 12 months. This remarkable analgesic effect, explored in Psychedelics and Drug Studies, suggests psilocybin's neuroplastic potential to disrupt neuropathic pain pathways. This finding, from Complementary and Alternative Medicine Studies, offers a compelling avenue for Medicine in treating severe chronic pain, potentially even for conditions like rheumatoid arthritis or fibromyalgia.
Abstract
Introduction: Outcomes of treatment for patients with Lupus have shown overall improvement and benefit from the more aggressive use of immunosuppre...
Biological embedding of early trauma: the role of higher prefrontal synaptic strength
European journal of psychotraumatology – August 29, 2023
Summary
Early trauma profoundly impacts brain function in individuals with PTSD. In the largest human sample (34 participants, 16 with PTSD) using <sup>13</sup>C MRS, early trauma correlated with increased glutamatergic synaptic strength, measured by Energy per Cycle (EPC). This enhanced neuroplasticity, driven by glutamate neurotransmitter cycling, linked to reduced behavioral inhibition and stronger reward responses. These Neuroscience findings inform Clinical psychology and Medicine, suggesting treatments affecting glutamate receptor activity, synaptic plasticity, and excitotoxicity, impacting memory and neural mechanisms.
Abstract
Background: Early trauma predicts poor psychological and physical health. Glutamatergic synaptic processes offer one avenue for understanding this ...
Psychedelics promote plasticity by directly binding to BDNF receptor TrkB
Nature Neuroscience – June 01, 2023
Summary
A compelling Neuroscience discovery reveals psychedelics like LSD and psilocin exert antidepressant effects by directly binding to Tropomyosin receptor kinase B (TrkB), a key Brain-derived neurotrophic factor (BDNF) receptor. These compounds show affinities 1,000-fold higher for TrkB than conventional antidepressants, promoting neuroplasticity. Psychedelics and Drug Studies indicate this profound impact on Psychology and behavior is TrkB-dependent, driven by neurotrophic factors, and separate from hallucinogenic effects, which involve other neurotransmitter receptors. This opens avenues for non-hallucinogenic treatments.
Abstract
Abstract Psychedelics produce fast and persistent antidepressant effects and induce neuroplasticity resembling the effects of clinically approved a...
Mini-review: The neurobiology of treating substance use disorders with classical psychedelics
Frontiers in Neuroscience – April 17, 2023
Summary
Since the 1960s, psychedelics have shown persistent potential for treating substance use disorders. This Neuroscience narrative review synthesizes knowledge on how serotonergic hallucinogens, like psilocybin, influence behavior. Molecular neuroscience reveals they induce neuroplasticity and alter gene expression, impacting neurotransmitter receptor influence on behavior. While Psychology and Psychedelics and Drug Studies explore this, the precise biochemical mechanisms countering addiction's neuronal changes remain largely unknown. Further understanding is vital for potential psychotherapeutic applications.
Abstract
The potential of psychedelics to persistently treat substance use disorders is known since the 1960s. However, the biological mechanisms responsibl...
A novel framework for ketamine-assisted couple therapy.
Frontiers in psychiatry – January 01, 2024
Summary
Psychedelic therapies are revolutionizing mental health treatment, and now they're transforming relationships too. Ketamine-assisted psychotherapy shows promise in helping couples overcome relationship challenges while addressing individual mental health concerns. The treatment combines traditional couple therapies with ketamine sessions, promoting neuroplasticity and emotional openness between partners.
Abstract
Intimate relationship distress is prevalent and is associated with poorer health, mental health, and mortality outcomes. Evidence-based couple ther...
Fluoxetine and Ketamine Enhance Extinction Memory and Brain Plasticity by Triggering the p75 Neurotrophin Receptor Proteolytic Pathway.
Biological psychiatry – February 01, 2025
Summary
Popular antidepressants fluoxetine and ketamine work in surprising ways to enhance memory and brain adaptability. These medications bind to specific brain receptors, triggering a cascade that helps eliminate fearful memories while promoting brain plasticity. The process involves a delicate balance of protein interactions that strengthen the brain's natural ability to rewire itself, offering hope for better mental health treatments.
Abstract
Diverse antidepressants were recently described to bind to TrkB (tyrosine kinase B) and drive a positive allosteric modulation of endogenous BDNF (...
Classic Psychedelic Drugs: Update on Biological Mechanisms
Pharmacopsychiatry – January 25, 2022
Summary
Psychedelics profoundly re-engineer brain function, offering new therapeutic avenues. Over two decades, Neuroscience has revealed these substances primarily target serotonergic receptor subtypes, crucial for information processing. This Neurotransmitter Receptor Influence on Behavior modulates brain activity, fostering neuroplasticity in areas governing Cognition, Affect, and self-perception. Neuroimaging and Neuropsychology tasks demonstrate distinct changes in brain connectivity, linking subjective experiences to altered emotion regulation. Such insights from Cognitive psychology and Biochemical Analysis suggest re-shaping self-experience and emotional processing holds significant psychiatric promise.
Abstract
Abstract Renewed interest in the effects of psychedelics in the treatment of psychiatric disorders warrants a better understanding of the neurobiol...
On serotonin, psychedelics, entactogens and psychoplastogens in depression, anxiety, post-traumatic stress, and related disorders.
OpenAlex – May 23, 2024
Summary
Potent hallucinogens like psilocybin offer rapid, long-lasting antidepressant and anxiolytic effects for major depressive disorder and anxiety, often after just one or two administrations. Neuroscience and psychiatry reveal these psychedelics modulate the serotonin system, crucial for brain function and implicated in tryptophan-related disorders. Their chemical synthesis yields alkaloids showing promise in drug studies, achieving FDA breakthrough status for conditions involving neuroinflammation and neuroplasticity, revolutionizing psychology's approach to mental health.
Abstract
There is controversy about a causal role of serotonin (5-HT) in depression, some arguing that there is no proof for impaired brain 5-HT function in...
The Potential Role of Psilocybin in Traumatic Brain Injury Recovery: A Narrative Review
Brain Sciences – May 26, 2025
Summary
Psilocybin, a hallucinogen and alkaloid often produced via chemical synthesis, offers significant promise for Traumatic Brain Injury (TBI) recovery. A review of 45 articles in neuroscience and medicine suggests this psychedelic may reduce inflammation, promote neuroplasticity, and alleviate mood disorders common after TBI. These findings, crucial for psychology and drug studies, underscore psilocybin's pharmacology and therapeutic potential. Benefits observed in related conditions like depression further highlight its role in modern medicine.
Abstract
Background: This narrative review explores psilocybin’s potential use as a therapeutic agent in patients with traumatic brain injury (TBI). Methods...
[Mechanisms of action and therapeutic perspectives of LSD: Current status].
Biologie aujourd'hui – January 01, 2025
Summary
LSD uniquely modulates multiple brain systems, offering hope for rapid, sustained antidepressant effects. Studies reveal how psychedelics like LSD act as fast-acting antidepressants, especially for treatment-resistant depression. Findings suggest LSD enhances neuroplasticity, a promising path for dépression résistante au traitement, potentially complementing existing antidépresseurs à action rapide.
Abstract
Major depressive disorder (MDD) is a prevalent and disabling condition affecting over 350 million individuals worldwide. Although conventional anti...
Discovery of Rapid-Acting, Orally Available Antidepressants by Activating TrkB Signaling.
Journal of medicinal chemistry – July 29, 2025
Summary
Current antidepressants can take weeks to work, and rapid-acting options often have severe side effects. A new compound was discovered that rapidly alleviates depressive symptoms in preclinical models. This oral compound, unlike existing fast-acting treatments, activates crucial brain pathways, offering potent antidepressant effects with minimal side effects. It readily enters the brain, highlighting a promising avenue for rapid, safer depression relief by enhancing the brain's ability to adapt.
Abstract
Major depressive disorder (MDD) remains a significant global health burden, and its current treatments are limited by the delayed onset of efficacy...
Psilocybin
OpenAlex – May 01, 2025
Summary
Psilocybin, a potent hallucinogen derived from over 200 mushroom species, is demonstrating significant promise in psychology. This alkaloid, a focus of diverse academic research themes, enhances neuroplasticity, aiding individuals in meaning-making. Evidence suggests benefits for major depressive disorder, anxiety, and existential suffering. While legal access expands, ongoing psychedelics and drug studies continue exploring cardiac safety and therapeutic potential, including through chemical synthesis advancements.
Abstract
Abstract Psilocybin, a naturally occurring psychoactive compound found in more than 200 mushroom species, has an enduring history of use in sacred ...
Psychedelics as a Treatment for Alzheimer’s Disease Dementia
Frontiers in Synaptic Neuroscience – August 21, 2020
Summary
A compelling new frontier in Medicine suggests psychedelics like psilocybin, a potent hallucinogen, could revolutionize Dementia treatment. With no current disease-modifying options for Alzheimer's disease, Neuroscience and Psychiatry are exploring these compounds. Early Drug Studies highlight their potential to improve Cognition by stimulating neuroplasticity and reducing Neuroinflammation. This offers hope for managing this devastating Disease, influencing behavior through complex neurotransmitter receptor interactions. The focus is on micro-dosing these chemical synthesis alkaloids for therapeutic benefits, moving beyond their traditional Psychology context.
Abstract
Currently, there are no disease-modifying treatments for Alzheimer's disease (AD) or any other dementia subtype. The renaissance in psychedelic res...
From psychiatry to neurology: Psychedelics as prospective therapeutics for neurodegenerative disorders
Journal of Neurochemistry – September 14, 2021
Summary
Psilocybin, a potent hallucinogen, is revolutionizing psychiatry, uniquely improving major depressive disorder (MDD) symptoms long-term after a single treatment. This breakthrough in medicine led the FDA to grant "Breakthrough Therapy" status to two Phase III clinical trials for psilocybin. Beyond treating psychological disease, emerging neuroscience and drug studies suggest psychedelics may also treat brain injury and neurodegenerative conditions. These compounds foster neuroplasticity, offering new avenues for neurology and understanding neurotransmitter receptor influence on behavior.
Abstract
Abstract The studies of psychedelics, especially psychedelic tryptamines like psilocybin, are rapidly gaining interest in neuroscience research. Mu...
Temporal dynamics in neuroimaging as correlates of therapeutic response to psilocybin in major depressive disorder: A systematic review and critical appraisal
Journal of Affective Disorders – September 16, 2025
Summary
Psychedelic drug studies reveal psilocybin, an alkaloid often produced via chemical synthesis, offers compelling promise for depression. Its neurotransmitter receptor influence on behavior is linked to dynamic neuroplastic changes, with clinical improvement observed in 65% of participants and changes across 15 brain regions. However, many analyses used overlapping datasets, raising bias concerns and limiting generalizability. Rigorous, independent investigations with pre-registered designs are crucial to confirm these mechanisms.
Abstract
Although these findings suggest psilocybin is associated with dynamic and temporally distinct neuroplastic changes linked to clinical improvement, ...
Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomised semi-naturalistic-lab feasibility study
OpenAlex – October 11, 2023
Summary
Daily executive functions significantly improved for individuals undergoing psilocybin-assisted neurofeedback. This approach, combining a potent psychedelic from chemical synthesis with targeted brain training, leverages neuroplasticity to enhance mental flexibility. In a group of 18 participants, self-reported gains in working memory and inhibition showed medium to high effect sizes. While 19 controls also reported some benefits, the experimental group achieved their key training goals. This suggests a promising avenue in Psychology and Physical medicine and rehabilitation, exploring neurotransmitter receptor influence on behavior through novel Psychedelics and Drug Studies.
Abstract
Executive function deficits, common in psychiatric disorders, hinder daily activities and may be linked to diminished neural plasticity, affecting ...
PSYCHEDELICS IN PSYCHIATRY - OVERVIEW OF PSILOCYBIN RESEARCH
International Journal of Innovative Technologies in Social Science – September 01, 2025
Summary
Psilocybin, a potent hallucinogen, is emerging as a groundbreaking treatment in Psychiatry. An overview of 26 diverse academic research themes, including Psychedelics and Drug Studies, reveals its significant antidepressant effects for Major Depressive Disorders. This compound, derived through chemical synthesis and alkaloids, enhances neuroplasticity and cognitive flexibility. While established in Psychology for depression, preliminary findings also show promise for Anorexia Nervosa. Psilocybin offers a novel therapeutic approach, moving beyond traditional psychoanalysis by significantly improving mental health outcomes.
Abstract
Introduction: Recently, there has been a significant increase in interest in the use of psychedelics for various psychiatric conditions. Psilocybin...
Naturalistic Entheogenics
Philosophy and the Mind Sciences – April 19, 2022
Summary
Emerging drug studies show psilocybin can reduce severe depression by 50-70% in some patients, challenging traditional psychology. A core "Comforting Delusion Objection" questions if this therapeutic promise, often involving chemical synthesis and alkaloids, relies on non-naturalistic metaphysical beliefs, creating an epistemological dilemma for psychotherapists. Psychedelic therapy, rather than promoting delusion, alters self-representations, offering profound epistemic and spiritual benefits fully compatible with naturalism, moving beyond simple neuroplasticity or placebo effect in pain management.
Abstract
In this précis I summarise the main ideas of my book Philosophy of Psychedelics. The book discusses philosophical issues arising from the therapeut...
Evaluating Psilocybin as a Treatment for Neuropsychiatric Symptoms in Parkinson’s Disease
Global Journal of Medical Research – June 28, 2025
Summary
Psilocybin, a compelling hallucinogen and alkaloid, offers new hope for Parkinson's disease medicine. This psychedelic compound, increasingly explored in drug studies and potentially through chemical synthesis, may significantly improve both motor and non-motor symptoms, including those impacting psychiatry and psychology. It modulates brain systems, enhancing neuroplasticity. While clinical data for psilocybin in Parkinson's disease is currently limited, its therapeutic potential for this complex disease is compelling, suggesting a future where it could redefine patient care.
Abstract
Parkinson’s Disease (PD) is a progressive neurodegenerative disorder marked by motor symptoms due to dopaminergic degeneration and non-motor sympto...
Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder
Annals of Medicine and Surgery – November 24, 2025
Summary
Psilocybin delivers rapid, sustained relief for major depressive disorder, even when traditional treatments fail. Analysis of clinical studies from 2014 to 2024 reveals it acts on serotonin 5-HT2A receptors, boosting neuroplasticity and brain connectivity to alleviate symptoms. Despite this promising mechanism, its Schedule I classification and societal stigma severely restrict therapeutic application and further investigation. Overcoming these regulatory barriers is vital to integrate psilocybin into mainstream mental health care, unlocking its potential to transform depression treatment.
Abstract
Psilocybin, a naturally occurring psychedelic compound, has received attention as a novel therapeutic option for major depressive disorder (MDD), p...
Neurobiological and Therapeutic Potential of Psilocybin in Psychiatric Disorders
Journal of Pharma Insights and Research. – October 05, 2025
Summary
Psilocybin offers rapid, sustained antidepressant and anti-anxiety effects, particularly for treatment-resistant depression and existential distress. Administered within psychotherapy, it acutely disrupts key brain networks, like the Default Mode Network, creating a state of elevated brain entropy. This leads to enhanced neuroplasticity, fostering new neural connections and helping unlearn maladaptive cognitive patterns. Significant efficacy is evident, but careful screening and a supportive therapeutic setting are essential for safe, effective application.
Abstract
Psilocybin, an indoleamine alkaloid derived from various fungal species, is the subject of renewed, rigorous investigation for its therapeutic pote...
The Effect of Psilocybin on Cortical Neural Dynamics, Sleep-Wake Behavior, and Persistent Pain in a Rat Model
University of Michigan Library – January 01, 2025
Summary
Psilocybin, a serotonergic hallucinogen, demonstrates potent analgesic properties in rat models of persistent pain, extending its use beyond psychiatry. This medicine shows promise for chronic pain conditions like fibromyalgia and neuropathic pain, addressing nociplastic pain's complex etiology. Neuroscience reveals it promotes neuroplasticity and modulates neural networks, identifying 5-HT2A receptor targets. These psychedelics and drug studies lay foundational work for pain management, suggesting novel pain disorder treatment with limited adverse effects, reducing reliance on anesthesia for neuralgia.
Abstract
Psilocybin containing mushrooms have been utilized for ceremonial, medicinal, and spiritual purposes for millennia. Recently there has been a surge...
Epigenome-wide Association Study of Psilocybin-Induced Methylome Changes in Alcohol Use Disorder
OpenAlex – July 18, 2025
Summary
Psilocybin, a psychedelic alkaloid, appears to alter the epigenome, potentially explaining its lasting benefits for psychiatric conditions like alcohol use disorder. In 40 patients, a genome-wide association study of DNA methylation revealed changes after a 25mg dose. One CpG site in TLE4 and altered RASGRP4 methylation showed an association with psilocybin treatment. These epigenetic shifts relate to neuroplasticity and immune functions, suggesting a biological basis for reduced drinking behavior and depressive symptoms, crucial for psychology and psychiatry.
Abstract
Abstract The serotonergic hallucinogen psilocybin has shown potential as a treatment for psychiatric conditions like alcohol use disorder (AUD) and...
IS PSYCHEDELIC TREATMENT OF MENTAL HEALTH DISORDERS READY FOR PRIME TIME?
Journal of Pakistan Psychiatric Society – June 30, 2024
Summary
Psychedelics like Psilocybin and MDMA are transforming Psychiatry, offering hope for millions with mental health challenges. These powerful hallucinogens, including Lysergic acid diethylamide (used clinically from the 1950s-1967) and Ayahuasca, influence neurotransmitter receptors, altering consciousness. Clinical psychology and drug studies reveal their potential to disrupt pathological brain activity, promoting neuroplasticity. Psychotherapist-guided sessions, leveraging these chemical synthesis alkaloids, address anxiety and other conditions. This burgeoning field of Psychology suggests a new era for mental health treatment.
Abstract
Psychedelics, substances known to alter perception, mood, and consciousness, have been used across various cultures for centuries, often in religio...
The therapeutic efficacy of psilocybin in major depressive disorder: A review of recent clinical and mechanistic evidence
Zenodo (CERN European Organization for Nuclear Research) – January 26, 2026
Summary
Psilocybin, a potent hallucinogen, offers rapid, sustained antidepressant effects for major depressive disorder. Clinical trials, including randomized controlled trials, show large effect sizes and higher remission rates than conventional treatments, with benefits lasting up to a year. Functional neuroimaging reveals psilocybin's impact on neuroplasticity, reducing amygdala activity and altering the default mode network. While adverse effects are mild, the integration of clinical psychology support is crucial. This neuroscience breakthrough in psychiatry medicine holds significant promise for depressive symptoms.
Abstract
This review examines the therapeutic efficacy of psilocybin for major depressive disorder by integrating findings from clinical trials, meta-analys...
PSYCHEDELIC PHARMACOLOGY IN PSYCHIATRY: THE MECHANISMS AND THERAPEUTIC POTENTIAL OF PSILOCYBIN, MDMA, AND LSD IN MENTAL HEALTH DISORDERS
Journal of medical & health sciences review. – March 11, 2025
Summary
Psilocybin, MDMA, and Lysergic acid diethylamide (LSD) offer sustained relief for depression and PTSD after just a few sessions, a profound shift in Psychiatry. These powerful Hallucinogens, often produced via Chemical synthesis as alkaloids, are revolutionizing Medicine. Psychedelics and Drug Studies reveal their Pharmacology impacts neuroplasticity through serotonergic receptors, moving beyond traditional Psychology. While Mescaline is another related compound, the focus is on these specific agents, whose therapeutic efficacy is rigorously explored despite legal and ethical challenges.
Abstract
Psilocybin, MDMA, and LSD have recently emerged as popular psychedelic substances for use in psychopharmacology in managing various disorders inclu...
Reunion Neuroscience raises $103 million
C&EN Global Enterprise – May 20, 2024
Summary
A novel psychedelic drug, RE104, offers significantly shorter treatment times for mental health conditions. Unlike psilocybin therapy, which can last 6-8 hours, RE104 sessions are expected to take half that duration. This biotechnology innovation, developed by Reunion Neuroscience, recently secured $103 million to advance treatments for adjustment disorder and postpartum depression. Acting on the brain's serotonin 2A receptor, RE104 aims to boost neuroplasticity and create new neural pathways, a critical area in neuroscience and cognitive science.
Abstract
Reunion Neuroscience , a start-up focused on mental health, has raised a $103 million series A round, co-led by MPM BioImpact and the Novo Nordisk ...
Supplementary file 1_Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat.docx
OPAL (Open@LaTrobe) (La Trobe University) – August 06, 2025
Summary
Veterans struggling with mental illness experienced remarkable improvements following psilocybin retreats. Among 21 participants, depression scores plummeted by 65%, PTSD by 50%, and anxiety by 28%. Electroencephalography revealed brain changes reflecting neuroplasticity, suggesting enhanced emotional regulation and cognitive control. This clinical psychology finding offers a promising path in psychiatry and medicine for mental health, potentially influencing arousal and providing alternatives to typical treatments like Sertraline.
Abstract
Introduction Psilocybin, a serotonergic psychedelic, has shown therapeutic potential in treating mental health disorders by, amongst the many effec...
Supplementary file 2_Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat.docx
OPAL (Open@LaTrobe) (La Trobe University) – August 06, 2025
Summary
Veterans with traumatic brain injuries experienced profound mental health improvements following psilocybin retreats. Among 21 participants, clinical depression scores decreased by 65%, PTSD by 50%, and anxiety by 28%. This positions psilocybin as a promising tool in Psychiatry and Clinical Psychology for addressing mental illness. Electroencephalography revealed brain changes suggesting enhanced neuroplasticity and improved neural communication, offering a new frontier in Medicine. These significant psychological benefits, including reduced arousal, underscore psilocybin's potential to foster well-being and alleviate complex mental health challenges.
Abstract
Introduction Psilocybin, a serotonergic psychedelic, has shown therapeutic potential in treating mental health disorders by, amongst the many effec...
Hypothesis: The Psychedelic Ayahuasca Heals Traumatic Memories via a Sigma 1 Receptor-Mediated Epigenetic-Mnemonic Process
Frontiers in Pharmacology – April 05, 2018
Summary
Ayahuasca might uniquely heal traumatic memories by targeting their core emotional components. Neuroscience suggests its alkaloids, like DMT, activate SIGMAR1 receptors and inhibit monoamine oxidase. This neuropharmacological action facilitates retrieval of repressed traumatic memories, making them labile. During memory consolidation, enhanced neuroplasticity allows the fear response to be reprogrammed. Psychology indicates this could update the memory's significance. This Neuroscience and Neuropharmacology Research proposes Ayahuasca as a groundbreaking pharmacological treatment for PTSD.
Abstract
Ayahuasca ingestion modulates brain activity, neurotransmission, gene expression and epigenetic regulation. N,N-Dimethyltryptamine (DMT, one of the...
Psychedelics and potential benefits in “healthy normals”: A review of the literature
Journal of Psychedelic Studies – September 01, 2019
Summary
Psychedelics, a focus of modern Drug Studies, offer profound benefits beyond treatment, enhancing well-being in healthy individuals. These powerful hallucinogens, including compounds like Mescaline, foster enduring increases in Mindfulness and Prosocial behavior. Psychology reveals they boost Openness to experience, a key Personality trait, and improve Attunement to nature, impacting social psychology. Such experiences facilitate psychotherapeutic gains by modulating neuroplasticity, suggesting deeper biochemical mechanisms at play.
Abstract
We are in the midst of a psychedelic research renaissance. With research examining the efficacy of psychedelics as a treatment for a range of menta...
Psilocybin's Emerging Role in Combating Depressive Disorder
Journal of Education Health and Sport – August 08, 2023
Summary
A compelling finding in Mental Health Research Topics: Psilocybin, a naturally synthesized hallucinogen, shows remarkable promise for treating persistent depression and anxiety. Clinical psychology trials reveal that combined with psychotherapy, this psychedelic provides enduring alleviation of symptoms, with improvements largely equivalent to standard antidepressant medicine. Psilocybin influences the default mode network, fostering neuroplasticity and altering cognition. This neuroscience-backed approach in psychiatry could revolutionize medicine, offering new hope for widespread psychological challenges.
Abstract
In this review paper, we delve into the potential applicability of psilocybin - a naturally synthesized psychedelic substance found within select s...
5mC and 5hmC Detection Highlights How Psychedelics Affect Brain Epigenetic Patterns
Zenodo (CERN European Organization for Nuclear Research) – November 04, 2025
Summary
Psilocybin, a serotonergic compound, rapidly rewires brain biology, revealing profound antidepressant mechanisms. In 3 mice, 1,404 regions of 5-Hydroxymethylcytosine (5hmC) DNA demethylation appeared in the Prefrontal cortex. These Epigenetics changes, critical for glutamatergic neuroplasticity, act as a mediator. This Neuroscience insight into DNA methylation, explored in Psychedelics and Drug Studies, illuminates how biology sustains mood regulation. Findings inform Psychology, hippocampal formation, and forensic toxicology in conditions like Schizophrenia.
Abstract
Background: Psilocybin, a serotonergic psychedelic compound, has demonstrated long-term antidepressant effects, yet its underlying mechanisms remai...
Death risk: Lack of movement: The ignored pandemic of digitalization escalates the COVID-19 crisis
Technoetic Arts – June 01, 2021
Summary
The COVID-19 Pandemic has pushed us past a tipping point in digitalization, escalating physical inactivity and related diseases. This neglect fuels rising Loneliness and Anxiety, threatening global Medicine. Psychology highlights the urgency of integrating physical activity into daily life. Promisingly, combining exercise with microdosing psychedelics, as explored in Drug Studies, alongside Mindfulness and neuroplastic movement practices from Complementary and Alternative Medicine Studies, offers a sustainable path forward. This holistic approach is vital for future well-being, addressing issues beyond Body Image and Dysmorphia Studies.
Abstract
Data analysis from diverse medical fields suggests that we have reached a tipping point in the digitalization dynamic through the ongoing COVID-19 ...
A long trip into the universe: Psychedelics and space travel
Frontiers in Space Technologies – September 15, 2022
Summary
Long-duration space travel poses significant psychological challenges, impacting mood and perception. To bolster astronauts' mental well-being and consciousness during future astrobiology missions, integrating psychedelics is proposed. These plant and fungal molecules, explored in drug studies, could facilitate extended stays in space, akin to how citrus prevented scurvy in 18th-century sea travel. Their ability to modulate biological systems and promote neuroplasticity could be crucial for 21st-century deep space exploration, aiding in processing profound experiences.
Abstract
Prolonged periods in space have potentially deleterious physiological and psychological effects. Ensuring the physical health and mental well-being...
LSD induces increased signalling entropy in rats’ prefrontal cortex
OpenAlex – June 23, 2021
Summary
Psychedelics, like lysergic acid diethylamide (LSD), profoundly reorganize brain signalling by influencing neurotransmitter receptors. In rats, chronic LSD treatment fundamentally rewires gene networks within the prefrontal cortex, making them more complex and increasing signalling entropy—a key feature of neuroplasticity. This molecular entropy, revealed through biochemical analysis, mirrors patterns seen in human neuroimaging, suggesting how these drug studies influence cognition and behavior. This neuroscience insight into biology and synaptic plasticity offers new avenues for psychology and psychiatric treatment.
Abstract
Abstract Psychedelic drugs are gaining attention from the scientific community as potential new compounds for the treatment of psychiatric diseases...
Psychedelics and the Serotonin Hypothesis of Eating Disorders
Brain Sciences – August 21, 2025
Summary
Psychedelics like psilocybin offer a promising new avenue in clinical psychology for treating eating disorders such as bulimia nervosa and binge eating. This hallucinogen, influencing serotonergic neurotransmitter receptors, may enhance cognitive flexibility and neuroplasticity, addressing core psychopathology. Neuroscience and biochemical analysis suggest psilocybin's 5-HT2A receptor influence on behavior could provide psychological insight. Emerging psychedelics and drug studies highlight its potential, offering a distinct approach for psychotherapists in psychiatry to tackle entrenched cognition in these conditions. Preliminary evidence suggests improved symptoms and quality of life.
Abstract
Recent advances in psychedelic research have renewed interest in their therapeutic potential for psychiatric disorders characterized by cognitive a...
Accelerated recovery using magnesium ibogaine: characterizing the subjective experience of its rapid healing from neuropsychiatric disorders.
Npj mental health research – January 31, 2026
Summary
Magnesium-ibogaine rapidly improves TBI and PTSD in U.S. Special Operations veterans. Narratives from 30 male veterans revealed a profound healing experience. Participants described guided replay of traumatic memories, a sense of altered self and mystical connection, and deep emotional resolution with surges of forgiveness and renewed purpose. They also reported embodied healing, including vivid neural repair, cognitive clarity, and somatic relief. This accelerated, self-directed process suggests powerful mind-body mechanisms driving rapid neuroplastic change, offering new insights into trauma and TBI recovery.
Abstract
Magnesium-ibogaine, a formulation combining ibogaine with pre- and post-treatment magnesium, was recently found to yield rapid clinical improvement...
Bridging ancient substances and modern psychiatry: the role of classic psychedelics in depression treatment.
Neuroscience – January 22, 2026
Summary
Fewer than half of patients achieve remission with current Major Depressive Disorder (MDD) treatments, underscoring a critical need for new options. Classic psychedelics are emerging as a promising treatment. These substances interact with brain receptors, enhancing connectivity and promoting neuroplasticity—processes believed to alleviate depression symptoms. Studies indicate classic psychedelics yield favorable, long-term outcomes comparable to traditional therapies, offering a compelling new path for MDD management.
Abstract
Pharmacotherapy for MDD is commonly prescribed to patients, yet fewer than half achieve remission. Moreover, many patients exhibit intolerant respo...
Advancing treatment paradigms: the role of psilocybin in managing major depressive disorder.
Annals of medicine and surgery (2012) – January 01, 2026
Summary
Psilocybin offers remarkable promise, providing rapid and sustained symptom relief for major depressive disorder, even in treatment-resistant cases. Evidence from clinical trials conducted between 2014 and 2024 reveals this psychedelic therapy enhances neuroplasticity and brain connectivity. However, its classification as a Schedule I substance significantly impedes further research and broader application. Policy reform is crucial to overcome these regulatory barriers, allowing psilocybin's full potential to be unlocked and integrated into mainstream mental health care.
Abstract
Psilocybin, a naturally occurring psychedelic compound, has received attention as a novel therapeutic option for major depressive disorder (MDD), p...
The intersection of near-death experiences (NDEs) and traumatic brain injury (TBI): neurobiological, phenomenological, and creative implications.
Frontiers in human neuroscience – January 01, 2025
Summary
Traumatic brain injury (TBI) and near-death experiences (NDEs) can surprisingly catalyze profound human creativity. These extreme altered states profoundly impact neurobiology, reconfiguring brain networks to foster heightened artistic expression and significant personality and spiritual changes. Like psychedelic experience, TBI and NDEs demonstrate the brain's immense neuroplasticity. Understanding these transformations, perhaps through neuropharmacological insights into altered brain function, challenges traditional views of pathology. This unveils new frameworks for human potential, showing how extreme conditions can unlock hidden cognitive reservoirs.
Abstract
Traumatic brain injury (TBI) and near-death experiences (NDEs) represent profound disruptions in brain function, often associated with dramatic cha...
Ketamine in depression and electroconvulsive therapy
Current Opinion in Anaesthesiology – October 01, 2021
Summary
A single intravenous dose of 0.5 mg/kg of ketamine, administered over 40 minutes, delivers a powerful, rapid-onset antidepressant effect. This treatment can alleviate depression and suicidal thoughts within hours, with benefits potentially lasting up to a week. Ketamine and its analog esketamine conclusively demonstrate this swift impact, attributed to improved neuroplasticity in key brain areas. Repeated nasal spray esketamine may prevent depression relapse. Ketamine also enhances seizure quality and could diminish cognitive impairment during electroconvulsive therapy.
Abstract
Purpose of review The antidepressant effect of subanesthetic doses of ketamine was recognized 20 years ago. This review briefly summarizes the curr...
Basic aspects of ketamine therapy for treatment-resistant depression - a review paper
Quality in Sport – July 28, 2024
Summary
Up to 60% of major depression cases resist standard treatments, but ketamine offers a rapid, effective alternative. Its efficacy rivals electroconvulsive therapy, with a significantly faster onset than traditional antidepressants, quickly reducing suicide risk. The FDA approved esketamine for treatment-resistant depression in 2019. Ketamine's therapeutic benefits depend on form and dosage, likely involving brain neuroplasticity for its swift action.
Abstract
Introduction and purpose: Major depressive disorder (MDD) is the most common psychiatric illness, affecting millions of people worldwide. The first...
Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin
Journal of Psychopharmacology – November 04, 2020
Summary
Psilocybin, a psychedelic compound from "magic mushrooms," rapidly boosts gene expression linked to neuroplasticity, particularly in the prefrontal cortex. In a study with 20 rats, doses of psilocybin (0.5–20 mg/kg) significantly increased the expression of genes like Cebpb and Sgk1. The prefrontal cortex showed more pronounced changes than the hippocampus, highlighting its crucial role in plasticity. Notably, protein levels for key genes only partially matched transcription data, underscoring the need to evaluate protein translation alongside gene expression in understanding psilocybin's effects.
Abstract
Background: Psilocybin is a serotonergic psychedelic found in “magic mushrooms” with a putative therapeutic potential for treatment-resistant depre...
Ayahuasca potential benefits
European Psychiatry – April 01, 2021
Summary
Ayahuasca shows promise as a therapeutic tool for anxiety, depression, and addiction. Observational studies reveal significant reductions in depressive symptoms, with some participants experiencing decreased alcohol and cocaine use. A review of 100+ studies highlights its ability to promote introspection and emotional processing, akin to psychotherapy. Users often report improvements in mindfulness, comparable to those seen in meditators. The biochemical effects include enhanced neuroplasticity through 5HT2A agonism, suggesting potential benefits for cognition and mental health. Further investigation with larger samples is warranted.
Abstract
Introduction Ayahusca has potential therapeutic beneffits. Objectives Expose the potential beneffits of ayahuasca from neuropharmacology and clinic...
Vaporizable Formulation of 5-MeO-DMT and THCV as Prophylactic or Therapeutic Agent for Treatment-Resistant Depression (TRD) and Anxiety Disorders
Preprints.org – February 09, 2026
Summary
A novel treatment approach combines 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) and Tetrahydrocannabivarin (THCV) to address Treatment-Resistant Depression (TRD) and chronic anxiety. While 5-MeO-DMT provides rapid antidepressant effects, it can induce panic responses in some users. THCV, however, offers anxiolytic benefits without significant psychoactivity at lower doses. This innovative precision vaporization device delivers a specific ratio of both compounds, promoting neuroplasticity while mitigating anxiety, potentially transforming treatment for the 50% of individuals with TRD who do not respond to conventional medications.
Abstract
The global burden of mental health conditions, including Treatment-Resistant Depression (TRD) and chronic anxiety, has increased. Existing treatmen...
Lusaris launches with $60 million
C&EN Global Enterprise – November 07, 2022
Summary
Lusaris Therapeutics has secured $60 million in Series A financing to create innovative treatments for severe neuropsychiatric and neurological conditions. Their lead candidate targets treatment-resistant depression using a formulation of the psychedelic 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) delivered as a dissolvable tablet under the tongue. The compounds, known as serotonergic neuroplastogens, are designed to enhance neural plasticity, potentially revolutionizing approaches to mental health. Additionally, Lusaris has licensed advanced fast-dissolving tablet technology from Catalent for this promising therapy.
Abstract
Lusaris Therapeutics has launched with $60 million in series A financing to develop therapies for severe neuropsychiatric and neurological conditio...
LSD: Mechanisms and relevance to the treatment of depression
Neuroscience & Biobehavioral Reviews – October 10, 2025
Summary
Over 350 million people globally suffer from major depressive disorder (MDD), with around 30% experiencing treatment-resistant depression (TRD). Traditional antidepressants target neurotransmitters like serotonin but often fall short for many. Emerging therapies, particularly psychedelics like LSD, show promise in inducing rapid and lasting antidepressant effects by enhancing neuroplasticity. Ongoing clinical trials are evaluating LSD's efficacy and safety for TRD, potentially revolutionizing psychiatric treatment. This innovative approach could provide hope for patients unresponsive to conventional medications, underscoring the need for further exploration in this area.
Abstract
Major depressive disorder (MDD) is one of the most prevalent psychiatric conditions worldwide, affecting over 350 million people. Standard treatmen...
Ayahuasca and Its Main Component N,N-Dimethyltryptamine (DMT) for the Treatment of Mental Disorders: Mechanisms of Action, Clinical Studies, and Tools to Explore the Human Mind
Biomedicines – February 25, 2026
Summary
Ayahuasca, a traditional brew containing the powerful hallucinogen DMT, shows significant promise in treating treatment-resistant depression (TRD) and major depressive disorder (MDD). Current evidence highlights four phase II studies with 5-MeO-DMT and one with DMT for TRD, alongside two phase II trials with DMT fumarate for MDD. These compounds enhance neuroplasticity and reorganize brain networks linked to cognition and mood regulation. With growing interest in psychedelics, they not only offer therapeutic potential but also deepen our understanding of mental health and brain function.
Abstract
In recent years, psychopharmacology has experienced a significant challenge, highlighting a renewed and strong scientific interest in psychedelics ...
Ischemia-Induced Neurodegeneration in Glaucoma: Mechanistic Insights and Translational Opportunities for Psychoplastogen-Based Therapies
Pharmaceuticals – February 14, 2026
Summary
Glaucoma, affecting over 70 million people globally, is not just about high eye pressure; it’s a complex neurodegenerative disorder linked to ischemia and chronic inflammation. Retinal ganglion cells suffer from oxidative stress and neuroinflammation, leading to progressive visual pathway disconnection. Current treatments focus on lowering intraocular pressure but overlook neuroprotection. Emerging compounds like ketamine and psilocybin show promise in enhancing neuroplasticity and reducing inflammation, potentially addressing unmet therapeutic needs in glaucoma by promoting neuronal regeneration and improving synaptic health.
Abstract
Glaucoma is increasingly recognized as an ischemic neurodegenerative disorder that extends beyond elevated intraocular pressure (IOP) to involve co...
Psychedelics in the context of stress and psychiatric disorders: A new horizon in mental health treatment
Psychedelics. – October 14, 2025
Summary
Psychedelics like psilocybin and MDMA show promise in treating stress-related psychiatric disorders, which affect millions globally and often resist conventional treatments. Chronic stress significantly contributes to conditions such as depression and anxiety, impacting public health. These substances can alter consciousness and enhance neuroplasticity, potentially improving emotional processing and serotonin function. By exploring the mechanisms behind these effects, a transformative approach to mental health care could emerge, addressing the persistent challenges faced by individuals suffering from anxiety and depression.
Abstract
Psychiatric illness, particularly stress-related disorders including depression, anxiety and posttraumatic stress disorder, presents a considerable...
Simulating Synaptic Pruning and Ketamine-Like Recovery in Depression: Insights from Consolidation Duration and Iterative Regimens on Resilience and Relapse
Zenodo (CERN European Organization for Nuclear Research) – January 14, 2026
Summary
Excessive synaptic pruning during adolescence can significantly weaken neural circuits, contributing to major depressive disorder (MDD). In simulations with 396,000 weights, accuracy plummeted to 32% after removing 95%. A single regrowth cycle restored accuracy to about 97%, while extending consolidation periods improved performance by up to 55 percentage points and minimized relapse. Iterative regrowth cycles reduced residual sparsity below 1%, enhancing stress resilience and outperforming one-time restorations. These findings underscore the importance of tailored, multi-dose treatments for fostering long-term neuroplasticity and stability in MDD.
Abstract
Background: Major depressive disorder (MDD) is increasingly framed as a failure of neuroplasticity. Excessive synaptic pruning in adolescence can l...
The collective lie in ketamine therapy: a call to realign clinical practice with neurobiology
Frontiers in Psychiatry – September 22, 2025
Summary
Ketamine therapy is often misinterpreted as a consciousness-expanding treatment, but its true function lies in promoting neuroplasticity as an NMDA receptor antagonist. With a narrative review of clinical data, it reveals that the acute dissociative experience associated with ketamine-assisted psychotherapy (KAP) is not essential for effective treatment. Instead, lasting mental health improvements stem from neurobiological changes occurring days after administration. Prioritizing subjective experiences over biological processes risks distorting memory and undermining treatment potential, highlighting the need for evidence-based protocols in clinical practice.
Abstract
In recent years, ketamine therapy has become increasingly entangled with psychedelic culture, leading to widespread misinterpretation of its therap...
Network pharmacology of cellular targets in major depressive disorder and differential mechanisms of fluoxetine, ketamine and esketamine
Computational and Structural Biotechnology Journal – December 29, 2025
Summary
Antidepressants like ketamine provide rapid relief for major depressive disorder (MDD), acting through glutamatergic pathways and enhancing brain-derived neurotrophic factor (BDNF) levels, promoting neuroplasticity. A meta-analysis of 500 studies revealed that targeting key genes such as GSK3B and opioid receptor mu 1 (OPRM1) could improve treatment outcomes. Additionally, the nuclear factor kappa B (NFKB) was identified as a central regulator linking inflammation and synaptic plasticity. These findings suggest that focusing on these targets may enhance therapeutic strategies for MDD.
Abstract
Major depressive disorder (MDD) is a multifactorial mental health condition involving genetic, environmental, and neurobiological factors. Conventi...
MDMA in Psychiatry: From PTSD to emerging indications, safety, and future directions
Psychedelics. – October 14, 2025
Summary
MDMA, known for its therapeutic potential, has shown remarkable effects in treating resistant posttraumatic stress disorder (PTSD), with clinical trials indicating substantial improvements. In studies involving 100+ participants, MDMA-assisted psychotherapy led to significant reductions in PTSD symptoms. Additionally, large epidemiological studies reveal that MDMA users report 30% lower rates of depression and reduced suicidal thoughts. Animal studies suggest MDMA enhances stress resilience and neuroplasticity. Future efforts aim to refine dosing protocols and safety monitoring for broader applications in mental health treatment.
Abstract
MDMA, 3,4-methylenedioxymethamphetamine (“ecstasy,” “molly”), is a distinctive entactogen that reverses the serotonin (5-HT) transporter to increas...
MDMA enhances prefrontal plasticity and representational drift during fear extinction
OpenAlex – March 08, 2026
Summary
MDMA significantly enhances fear extinction by promoting structural and functional neuroplasticity in the brain. In a study involving mice, MDMA increased spine density in the medial prefrontal cortex by 30%, indicating heightened synaptic connections. Additionally, the infralimbic cortex showed improved correlation with reduced freezing behavior during extinction tasks. Over time, neural representations in MDMA-treated mice shifted more rapidly, particularly among neurons that suppressed activity in response to cues. These findings suggest MDMA's potential as a therapeutic agent for improving cognitive processes related to fear and anxiety.
Abstract
Abstract Fear extinction requires dynamic updating of cortical representations, yet the neural mechanisms underlying successful extinction remain p...
Neurorestorative Properties of Ibogaine: Linking Multi-Receptor Affinities to Remyelination and Metabolic Restoration
Acta Neuropsychiatrica – February 13, 2026
Summary
Ibogaine shows promise as a potential treatment for neuropsychiatric conditions, including substance use disorder and multiple sclerosis. Observational data suggest that a single dose can lead to symptom relief, with evidence indicating that ibogaine enhances myelination markers after opioid use. White matter pathology is prevalent in conditions like multiple sclerosis, often linked to decreased myelination and metabolic dysregulation. By interacting with various neurotransmitter receptors, ibogaine may reduce excitotoxicity and promote neuroplasticity, offering a compelling rationale for its exploration in central nervous system therapies.
Abstract
Ibogaine is a psychedelic alkaloid without an approved indication. Observational clinical research shows linkages between single administration of ...